Cancer pathology is of great importance, since it is the second leading cause of death worldwide, with a prospect of growth in the number of cases for the next decades. Current chemotherapy treatments are characterized by high cost and a relatively low therapeutic index and are associated with several side effects and tumor resistance. Therefore, many efforts have been focused on the search for new drugs with an improved pharmacological profile and tumor-resistant lineage activity, as well as the feasibility of new administration routes. In this regard, different approaches have been employed for the design of metal-based anticancer drugs, such as the development of new cisplatin analogue complexes, as well as complexes that may be more selective to the tumor environment. A very promising strategy involves the preparation of high oxidation state inert metal complexes, which may act as prodrugs, reaching the tumor target without prior reduction or significant transformations. Only inside the tumor mass, due to hypoxia conditions (low oxygen) not normally found in normal tissues, these compounds would be reduced, originating the active species which would then attack the target more easily. Copper, by presenting two oxidation states whose reduction potential is accessible within the range of the cellular redox potential, is a promising element. In this context, two copper(II) complexes and two platinum(II) complexes with the isomeric ligands 1- and 2-phenyl-1,2,3-triazole-4-carboxaldehyde oxime were synthesized in the present study, which have never before been explored in the context of Coordination Chemistry, with only the copper complexes, in theory, demonstrating the potential to act as bioreductive prodrugs. The complexes were characterized by elemental analysis (CHN and AAS), vibrational spectroscopy and thermogravimetry. EPR studies in solid state were performed for the copper(II) complexes, while the platinum(II) complexes were also characterized by 195Pt NMR. Computer modeling was used as a complementary resource for structural propositions and assignment of the vibrational bands of the complexes, with the exception of coordination compound [Cu2(mu-L1)2(HL1)(ClO4)2(OH2)]·2H2O (1), whose structure was determined by single crystal X-ray diffraction. The other mononuclear copper(II) complex is cis-[Cu(HL2)2Cl2] (2). On the other hand, the platinum(II) compounds are mononuclear and as expected, quadratic, according to the formulae cis-[Pt(HL1)2Cl2]1 H2O (3) and cis-[Pt(HL2)2Cl2] (4). The copper complexes were tested against the leukemic cell lines U937 and THP-1, with complex 1 and HL1 also being tested on normal PBMC blood cells. Both complexes reduced cell viability in a concentration-dependent manner in the tested tumor lines; The activity profile towards U937 cells was similar for 1 and 2. However, compound 1 was twice as active as 2 against cell line THP-1. It is worth noting that 1 was 23 percent more toxic against the leukemic cell line THP-1 when compared to normal PBMC cells. The platinum complexes, alternatively, were tested against the K562 cell line, chronic myeloid leukemia, and both demonstrated similar toxicity, approximately 5x higher than carboplatin.